Sanofi S.A., FR0000120578

Sanofi stock after-hours at EUR 71.50: minus 1.27 percent versus prior close

Published on 09/29/2026 at 19:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock was at EUR 71.50 after-hours at 7:04 p.m. CEST on September 29, 2026, down 1.27 percent versus the prior close at Lang & Schwarz. A September 14 partnership announcement remains in focus.

Modern pharmaceutical sterile fill-and-finish manufacturing facility interior with glass vial-filling machines and cleanroom workers in white suits
Sanofi FR0000120578 photorealistic sterile fill-and-finish facility with vial-filling machines and cleanroom workers, Illustration mit AI erstellt.

Sanofi stock was at EUR 71.50 after-hours at 7:04 p.m. CEST on September 29, 2026, down 1.27 percent versus the EUR 72.42 prior close at Lang & Schwarz.

Planned mature-medicines partnership

In a September 14, 2026 release, Sanofi said it intends to create a strategic partnership with Cheplapharm under which Cheplapharm would take over 20 mature medicines and three manufacturing sites. The sites are in Csanyikvölgy, Hungary; Jurong, Singapore; and Ploërmel, France. The commercial transfer is planned to begin in the first quarter of 2027, with the transaction expected to be completed in the third quarter of 2027, subject to consultation procedures, regulatory approvals and customary closing conditions. GlobeNewswire

Equity stake and guidance

As consideration, Sanofi said it would receive a 26.4 percent equity stake in Cheplapharm. The company also said the proposed transaction is not expected to affect its financial guidance for 2026. The medicines being divested include Lovenox/Clexane, excluding the United States. GlobeNewswire

Disclaimer...

en | FR0000120578 | SANOFI S.A. | boerse | 70199954 | bgmi